IL147477A - Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemia - Google Patents
Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemiaInfo
- Publication number
- IL147477A IL147477A IL147477A IL14747796A IL147477A IL 147477 A IL147477 A IL 147477A IL 147477 A IL147477 A IL 147477A IL 14747796 A IL14747796 A IL 14747796A IL 147477 A IL147477 A IL 147477A
- Authority
- IL
- Israel
- Prior art keywords
- citicoline
- agents
- ischemia
- therapeutic agent
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 weeks. The method is useful in the treatment of stroke and severe head trauma patients and maximizes the chances for a full or substantially full recovery of the patient.
[US5872108A]
Claims (28)
1. A pharmaceutical composition, comprising: a) a therapeutically effective amount of citicoline or salt thereof; b) a therapeutically effective amount of a second therapeutic agent; and c) a pharmaceutically acceptable carrier; with the proviso that cytidine diphosphoethanolamine, cytidine diphospho-N-methylethanolamine, cytidine diphospho- N,N- dimethyl ethanolamine or mixtures thereof, are excluded.
2. A pharmaceutical composition- for protecting brain tissue from cerebral infarction subsequent to ischemia in a subject, comprising a) an amount of citicoline or salt thereof, that is effective in protecting brain tissue from cerebral infarction subsequent to ischemia in a subject; b) a therapeutically effective amount of a second therapeutic agent; and c) a pharmaceutically acceptable carrier; with the provision that cytidine diphosphoethanolamine, cytidine diphospho-N-methylethanolamine, cytidine diphospho-- N,Ndimethyl ethanolamine or mixtures thereof, are excluded.
3. The pharmaceutical composition of claim 2 wherein said amount of citicoline or salt thereof ranges from about Ί00 mg to about 4000 mg of citicoline and wherein said therapeutically effective amount of said second therapeutic agent is from about 10 mg to about 500 mg.
4. The pharmaceutical composition of claim 3 wherein said amount of citicoline or salt thereof ranges from about 100 mg to about 1000 mg of citicoline, wherein said second therapeutic agent is aspirin and wherein said therapeutically effective amount of said aspirin is from about 50 mg to about 500 mg.
5. The pharmaceutical composition of claim 4 wherein said therapeutically effective amount of said aspirin is from about 70 mg to about 300 mg.
6. The pharmaceutical composition of claim 4 wherein said amount of citicoline or salt thereof ranges from about 300 mgto about 700 mgof citicoline. 147477/5 34
7. The pharmaceutical composition of claim 4 wherein said amount of citicoline or salt thereof ranges from about 400 mg to about 600 mg of citicoline, "/'herein said second therapeutic agent is aspirin and wherein said therapeutically effective amount of said aspirin is from about 70 mg to about 90 mg.
8. The composition according to claim 2 wherein said ischemia occurs in the brain.
9. The composition according to claim 2 wherein said subject is a human.
10. The composition according to claim 2 wherein said subject has suffered a cerebral ischemia, head trauma or stroke.
11. 1 1. The composition of claim 1 or 2 wherein said second therapeutic agent is selected from a group consisting of antiplatelet agents, anticoagulant agents, thrombolytic and related agents, anti-ischemic agents, neuroprotectives, calcium channel blockers, agents targeted at nitric oxide, agents targeted at various neurotransmitters, cytokines, hormones and related products, free-radical scavengers, gangliosides and related products, modulators of various specific enzymes, memory enhancers or nootropics, neuroprotectives with diverse actions, haemorrheological agents and blood substitutes, imaging agents and contrast agents.
12. The composition of claim 1 or 2 wherein said second therapeutic agent is selected from a group consisting ofNMDA, t-PA, streptokinase, urokinase, aspirin and dipyridamole.
13. Use of citicoline or salt thereof, together with a second therapeutic agent in the manufacture of a medicament for protecting brain tissue from cerebral infarction subsequent to ischemia in a subject, with the proviso that cytidine diphosphoethanolamine, cytidine diphospho-N-methylethanolamine, cytidine diphospho-N,N-dimethylethanolamine or mixtures thereof, are excluded.
14. Citicoline or salt thereof, together with a second therapeutic agent for use as a medicament for the protection of brain tissue from cerebral infarction subsequent to ischemia in a subject, with the proviso that cytidine diphosphoethanolamine, cytidine diphospho-N-methylethanolamine, cytidine diphospho-N,N-dimethylethanolamine or mixtures thereof, are excluded.
15. The use of claim 13 or 14 wherein said second therapeutic agent is selected from a group consisting of antiplatelet agents, anticoagulant agents, thrombolytic and related agents, anti-ischemic agents, neuroprotectives, calcium channel blockers, agents targeted at nitric oxide, agents targeted at various neurotransmitters, cytokines, hormones and related products, free-radical scavengers, gangliosides and related products, modulators of various specific enzymes, memory enhancers or nootropics, neuroprotectives with diverse actions, haemorrheological agents and blood substitutes, imaging agents and contrast agents.
16. The use of claim 13 or 14 wherein said second therapeutic agent is selected from a group consisting of NMDA, t-PA, streptokinase, urokinase, aspirin and dipyridamole.
17. The use according to claim 14 within about 24 hours, after the occurrence of said ischemia.
18. The use according to claim 14 within about 12 to about 15 hours after the occurrence of said ischemia.
19. The use according to claim 14 for a period of at least about 30 days after the occurrence of said ischemia.
20. The use according to claim 14 for a period of at least about 4-8 weeks after the occurrence of said ischemia.
21. The use according to claim 14 for a period of at least about six months to about one year after the occurrence of said ischemia.
22. The use according to claim 13 or 14 wherein said ischemia occurs in the brain.
23. ■23. The use according to claim 13 or 14 wherein said subject is a human.
24. The use according to claim 13 or 14 wherein said subject has suffered a cerebral ischemia, head trauma or stroke. 147477/3 36
25. 2.5. The use according to claim 14 wherein said citicoline or salt thereof and said second therapeutic agent are used simultaneously.
26. The use according to claim 14 wherein said citicoline or salt thereof and said second therapeutic agent are used sequentially.
27. The pharmaceutical composition according to anyone of claims 1-12, substantially as herein described with reference to the examples and drawings.
28. The use according to anyone of claims 13-26, substantially as herein described with reference to the examples and drawings. g:\pctros20Q7\9006\l 8\aniended pages.doc/kh*
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39926295A | 1995-03-06 | 1995-03-06 | |
| US08/603,102 US5872108A (en) | 1995-03-06 | 1996-02-20 | Reduction of infarct volume using citicoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL147477A true IL147477A (en) | 2010-02-17 |
Family
ID=23578854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL147477A IL147477A (en) | 1995-03-06 | 1996-03-05 | Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemia |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US5872108A (en) |
| KR (1) | KR19980702724A (en) |
| IL (1) | IL147477A (en) |
| IN (1) | IN182555B (en) |
| ZA (1) | ZA961791B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002394A (en) * | 1995-10-02 | 1999-12-14 | Starsight Telecast, Inc. | Systems and methods for linking television viewers with advertisers and broadcasters |
| HUP0101235A3 (en) * | 1997-12-24 | 2002-04-29 | Ferrer Int | Hyperhydrated citicoline, process for preparing it and use |
| US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
| ES2169986B1 (en) * | 2000-03-14 | 2003-06-16 | Ferrer Int | USE OF CDP-HILL FOR PROFILACTIC TREATMENT OF CEREBRAL ISCHEMIA. |
| AU2001247759A1 (en) * | 2000-03-24 | 2001-10-08 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| US7235649B2 (en) * | 2000-03-24 | 2007-06-26 | Duke University | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same |
| US7034054B2 (en) * | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| WO2003100570A2 (en) * | 2002-05-23 | 2003-12-04 | New England Medical Center Hospitals, Inc. | Computer-assisted multi-dimensional patient selection |
| US9572830B2 (en) * | 2004-05-13 | 2017-02-21 | Massachusetts Institute Of Technology | Uridine effects on dopamine release |
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| JP5374162B2 (en) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | Modulation of redox-activated therapeutic side chain variants and energy biomarkers for the treatment of mitochondrial diseases and other conditions |
| HUE037592T2 (en) | 2009-08-26 | 2018-09-28 | Bioelectron Tech Corp | Methods for the prevention and treatment of cerebral ischemia |
| JP2011178687A (en) * | 2010-02-26 | 2011-09-15 | Kochi Univ | Preventive and/or therapeutic agent for pain caused by hematopoietic cell transplantation |
| WO2012164563A1 (en) | 2011-06-01 | 2012-12-06 | Brain Watch Ltd. | Isotopically labeled cdp-choline and uses thereof |
| AU2013268725B2 (en) | 2012-05-31 | 2017-02-16 | Asahi Kasei Pharma Corporation | Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent |
| CN113024369A (en) | 2015-12-17 | 2021-06-25 | Ptc医疗公司 | Compounds for the treatment of oxidative stress disorders |
| US11497795B2 (en) | 2018-09-28 | 2022-11-15 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5517769B2 (en) * | 1972-01-10 | 1980-05-14 | ||
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| IT1207106B (en) * | 1980-04-18 | 1989-05-17 | Made Italiana Srl Ora Searle I | PHARMACEUTICAL PREPARATION CONTAINING CITIDIN DISFOFOCOLINA ABSORBABLE ORALLY |
| JPS6043078B2 (en) * | 1980-10-31 | 1985-09-26 | 株式会社興人 | Production method of choline cytidine diphosphate |
| JPS6043079B2 (en) * | 1980-12-25 | 1985-09-26 | 株式会社興人 | Method for producing choline cytidine diphosphate |
| JPS57108099A (en) * | 1980-12-25 | 1982-07-05 | Kohjin Co Ltd | Preparation of choline cytidine diphosphate |
-
1996
- 1996-02-20 US US08/603,102 patent/US5872108A/en not_active Expired - Lifetime
- 1996-03-05 ZA ZA961791A patent/ZA961791B/en unknown
- 1996-03-05 IL IL147477A patent/IL147477A/en not_active IP Right Cessation
- 1996-03-06 IN IN347MA1996 patent/IN182555B/en unknown
- 1996-03-06 KR KR1019970706131A patent/KR19980702724A/en not_active Application Discontinuation
-
1997
- 1997-03-18 US US08/820,244 patent/US5801160A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR19980702724A (en) | 1998-08-05 |
| ZA961791B (en) | 1996-09-10 |
| US5872108A (en) | 1999-02-16 |
| IN182555B (en) | 1999-05-01 |
| US5801160A (en) | 1998-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL147477A (en) | Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemia | |
| UA40589C2 (en) | method for treating a human suffering from viral infection, pharmaceutical composition, combination of compounds for the preparation of medications and pharmaceutical combination | |
| IE892061L (en) | Therapeutic nucleosides | |
| EP1014996A4 (en) | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses | |
| HK1003978A1 (en) | Composition for the treatment of schizophrenia | |
| RU2005104418A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS CONTAINING DEXTROMETORFAN AND QUINIDIN | |
| DK0642335T4 (en) | Controlled-release morphine-containing salt | |
| WO1993017020A3 (en) | Therapeutic nucleosides | |
| YU209288A (en) | Process for producing compound for treating, which contains azelastin for use in nose and/or eye | |
| ES2150294T3 (en) | COMPOSITION OF L-DOPA ESTERS. | |
| KR950703951A (en) | ANTIPYRETIC AND ANALGESIC METHODS AND COMPOSITIONS CONTAINING OPTICALLY PURE R-KETOROLAC | |
| CA2459470A1 (en) | Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use | |
| LU88684I2 (en) | Amphotericin b lipid complex and their pharmaceutically acceptable derivatives (abelcet) | |
| US4849426A (en) | Method for treating actinic keratosis with cytotoxic agents | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| BR9401199A (en) | Drug preparations, process for the preparation of a medicine preparation, process for the preparation of a medicine formulation. | |
| CA2314571A1 (en) | Methods and compositions for treating diseases and conditions of the eye | |
| TR200000149T2 (en) | Compositions for the prevention of cerebral neurovascular disorders, muscular headaches | |
| HU213677B (en) | Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them | |
| Farris et al. | Cytarabine treatment of herpes simplex encephalitis | |
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| HUP0001526A2 (en) | Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions | |
| IE892654L (en) | Therapeutic nucleosides | |
| EP0387757B1 (en) | Use of 5'-deoxy-5'methylthioadenosine, S-adenosylmethionine and their salts in the preparation of pharmaceutical compositions favouring hair growth in subjects suffering from baldness | |
| BRPI0415322A (en) | antiretroviral pharmaceutical composition, process for the preparation of an antiretroviral pharmaceutical composition, method for reducing the burden of pill consumption for a patient, method for increasing lamivudine and zidovudine half-life while not affecting nevirapine half-life |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| EXP | Patent expired |